$9.97
-0.30%
2026-09-04 09:47:06 EDT-$0.03
의료
생명공학
NASDAQ
활발히 거래 중
ImmuCell Corporation은 동물 건강 분야 기업으로서, 낙농 및 육우의 활력과 생산성을 향상시키기 위한 제품의 개발, 제조, 상용화를 전문으로 하며 미국 국내 시장과 ...
ImmuCell Corporation은 동물 건강 분야 기업으로서, 낙농 및 육우의 활력과 생산성을 향상시키기 위한 제품의 개발, 제조, 상용화를 전문으로 하며 미국 국내 시장과 ...
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Sep 16, 2028 | te Boekhorst Paul Francis Olivier | director, officer: President and CEO | Non Qualified Stock Option (right to buy) | — | 25,329 | $5.90 |
| Jun 18, 2026 | te Boekhorst Paul Francis Olivier | director, officer: President and CEO | Common Stock, par value $.01 per share | A | 8,000 | $9.49 |
| Apr 15, 2026 | DiMarco Anthony | director | Non Qualified Stock Options (Right to buy) | — | 17,899 | $7.60 |
| Apr 15, 2026 | Guillemette Gilles | director | Non Qualified Stock Options (Right to buy) | — | 17,899 | $7.60 |
| Apr 15, 2026 | Turner Kathy V | director | Non Qualified Stock Options (Right to buy) | A | 17,899 | $7.60 |
매수/매도 주식 수와 종가 추세(공통 일간 가격 소스)
X축: 주식 수, 총 주식 수 내림차순
X축: 건수, A+D 건수 내림차순
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 | 금액 |
|---|---|---|---|---|---|---|---|
| Sep 16, 2028 | te Boekhorst Paul Francis Olivier | director, officer: President and CEO | Non Qualified Stock Option (right to buy) | — | 25,329 | $5.90 | $149,441.10 |
| Jun 18, 2026 | te Boekhorst Paul Francis Olivier | director, officer: President and CEO | Common Stock, par value $.01 per share | A | 8,000 | $9.50 | $75,960.00 |
| Apr 15, 2026 | DiMarco Anthony | director | Non Qualified Stock Options (Right to buy) | — | 17,899 | $7.60 | $136,032.40 |
| Apr 15, 2026 | Guillemette Gilles | director | Non Qualified Stock Options (Right to buy) | — | 17,899 | $7.60 | $136,032.40 |
| Apr 15, 2026 | Turner Kathy V | director | Non Qualified Stock Options (Right to buy) | A | 17,899 | $7.60 | $136,032.40 |
| Apr 15, 2026 | Tomsche David Scott | director | Non Qualified Stock Options (Right to buy) | A | 11,933 | $7.60 | $90,690.80 |
| Apr 15, 2026 | Basse Gloria F | director | Non Qualified Stock Options (Right to buy) | A | 11,933 | $7.60 | $90,690.80 |
| Apr 15, 2026 | Wainman Paul R | director | Non Qualified Stock Options (Right to buy) | A | 11,933 | $7.60 | $90,690.80 |
| Apr 1, 2026 | Turner Kathy V | director: | — | — | 0 | — | — |
| Mar 20, 2026 | BRIGHAM MICHAEL F | director | Common Stock, par value $.01 per share | A | 25,000 | $5.84 | $146,000.00 |